Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26065141 | 0.75 | EBP (0.38) | CRHR1CNR2 | |
| SCHEMBL21780683 | 0.74 | CRHR1 (0.57) | CRHR1GRM2TGFBR1GAACRHR2 | |
| SCHEMBL21768453 | 0.74 | GRM2 (0.46) | CRHR1CNR2GRM2TGFBR1GAA | |
| SCHEMBL4559955 | 0.74 | CRHR1 (0.41) | CRHR1CNR2GRM2TGFBR1GAA | |
| SCHEMBL26065137 | 0.73 | NAMPT (0.38) | GAA | |
| SCHEMBL25369913 | 0.72 | EBP (0.34) | CRHR1CNR2TGFBR1 | |
| SCHEMBL2686133 | 0.72 | CRHR1 (0.39) | CRHR1CNR2GRM2TGFBR1GAA | |
| SCHEMBL25371509 | 0.71 | TGFBR1 (0.33) | CRHR1CNR2TGFBR1 | |
| SCHEMBL19105610 | 0.71 | CRHR1 (0.41) | CRHR1CNR2GRM2TGFBR1GAA | |
| SCHEMBL4464891 | 0.70 | RAB9A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4482587-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | CRHR1 3605/4885CNR2 4374/4885GRM2 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.